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A Phase II Study of Carboplatin, Etoposide, and Exisulind in
Patients with Extensive Small Cell Lung Cancer
CALGB 30104
Ramaswamy Govindan, MD,* Xiaofei Wang, PhD,† Maria Q. Baggstrom, MD,*
Susan Burdette-Radoux, MD,‡ Lydia Hodgson, MS,† Everett E. Vokes, MD,§
and Mark R. Green, MD, for the Cancer and Leukemia Group B
Purpose: To assess the efficacy and toxicity of carboplatin, etopo-
side, and exisulind as initial therapy for extensive stage small cell
lung cancer.
Patients and Methods: The Cancer and Leukemia Group B con-
ducted a phase II study of carboplatin (area under the curve 6) day
1 and etoposide 80 mg/m2 days 1–3 administered intravenously
every 21 days with exisulind 250 mg orally twice daily in 44
evaluable patients with previously untreated extensive stage small
cell lung cancer. The hypothesis was the addition of a novel cytostatic
agent to standard therapy may increase survival time. The primary end
point of the study was to evaluate overall survival. The secondary end
points were to characterize response rates and toxicity.
Results: The majority of the patients were male (64%), Caucasian
(95%), and had performance status 0 or 1 (77%). The median age
was 61 (range 44–82) years. The percentage of patients alive at 1
year was 36.4% (95% confidence interval CI: 24.6–53.8%). The
median overall survival was 10.6 months (95% CI: 9.1–14.7). The
best overall response rate was 77% (95% CI: 62–89%) with 16% of
the patients achieving complete response. The most frequent grade
3 or grade 4 hematological toxicities were neutropenia (64%),
thrombocytopenia (36%), and febrile neutropenia (16%). The most
common grade 3 or grade 4 nonhematological toxicities were
gastrointestinal (30%) and electrolyte changes (23%).
Conclusions: The addition of exisulind to a standard regimen of
carboplatin and etoposide did not improve outcomes compared with
historic controls treated with chemotherapy alone. Further evalua-
tion of this regimen in small cell lung cancer is not warranted.
Key Words: Small cell lung cancer, Phase II, Carboplatin, Etopo-
side, Exisulind, CALGB.
(J Thorac Oncol. 2009;4: 220–226)
Lung cancer is the leading cause of cancer-related death inthe United States.1 Small cell lung cancer accounts for
approximately 13% of all cases of lung cancer.2 Small cell
lung cancer is characterized by rapid tumor proliferation,
acute onset of symptoms, and rapidly progressive disease if
left untreated. Nearly two thirds of patients with small cell
lung cancer present with extensive stage disease.
The combination of cisplatin and etoposide has been
studied extensively in patients with small cell lung cancer.
Despite the impressive initial responses, nearly all patients
relapse and die of recurrent disease within 2 years.3 The
substitution of carboplatin for cisplatin results in similar
response rates and outcomes.4 Despite three decades of active
clinical research, median survival in extensive stage small
cell lung cancer (ES-SCLC) has not changed appreciably.
Novel approaches are desperately needed.
Exisulind (OSI Pharmaceuticals, Melville, NY) is a
sulfone derivative of sulindac, a nonsteroidal antiinflamma-
tory drug.5 Exisulind induces apoptosis and inhibits growth of
tumor cell lines of diverse origins, including lung. Exisulind
induces apoptosis in colonic tumor cell lines by inhibiting
guanosine 3, 5-cyclic monophosphate (cGMP) phosphodi-
esterase with a resulting increase in cGMP, and by inducing
cGMP-dependent protein kinase. This results in apoptosis
through protein kinase G-mediated  catenin phosphoryla-
tion.6 Exisulind has been shown to have synergistic cyto-
toxicity in combination with chemotherapy in preclinical
studies7,8 including cell lines that overexpress multidrug
resistance-associated protein (MRP).7 Overexpression of
MRP perhaps contributes to the eventual development of
drug resistance in small cell lung cancer.9 Addition of exisu-
lind to combination chemotherapy could potentially reverse
MRP-induced drug resistance. Exisulind is administered
orally and is well tolerated.
*Washington University School of Medicine and Alvin J. Siteman Cancer
Center, St. Louis, Missouri; †Cancer and Leukemia Group B Statis-
tical Center, Duke University, Durham, North Carolina; ‡Vermont
Cancer Center, University of Vermont, Burlington, Vermont; §University
of Chicago, Chicago, Illinois; and Care Alliance Roper Hospital,
Charleston, South Carolina.
Disclosure: Dr. Govindan has consulted with Lilly, AstraZeneca, Genentech,
and Pfizer. Dr. Vokes has consulted with the organization and received
honoraria. The other authors declare no conflicts of interest.
Address for correspondence: Ramaswamy Govindan, MD, Washington Uni-
versity School of Medicine, Box 8056, 660 South Euclid Avenue, St.
Louis, MO 63110. E-mail: rgovinda@dom.wustl.edu
The content of this manuscript is solely the responsibility of the authors and
does not necessarily represent the official views of the National Cancer
Institute.
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0402-0220
Journal of Thoracic Oncology • Volume 4, Number 2, February 2009220
Cancer and Leukemia Group B (CALGB) 30104 is a
single arm phase II study designed to evaluate the efficacy and
toxicity of the combination of exisulind, carboplatin, and eto-
poside for the treatment of chemotherapy—naive ES-SCLC.
This study was proposed for the following reasons: exisulind
has been shown to inhibit tumor growth and promote apo-
ptosis in vitro, has no overlapping toxicities with carboplatin
and etoposide, and has been shown to have synergistic cyto-
toxicity with etoposide-based chemotherapy. In addition,
because MRP plays a significant role in the development of
drug resistance, the ability of exisulind to reverse MRP-
induced drug resistance was worth studying in small cell
lung cancer. The primary objective of the study was to
increase overall survival and secondary objectives were
increased response rates and toxicities compared with
historical control.
PATIENTS AND METHODS
Patients
All patients had histologically or cytologically docu-
mented ES-SCLC. All patients had to have measurable dis-
ease according to the Response Evaluation Criteria in Solid
Tumors (RECIST)10 by the National Cancer Institute. Other
eligibility criteria included age 18 years, Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0 to 2,
and no prior chemotherapy for small cell lung cancer. Pa-
tients with uncontrolled brain metastases were excluded.
Prior radiation was allowed. Patients who were pregnant
and/or nursing as well as patients with a known hypersensi-
tivity to sulindac were excluded. Patients with an uncon-
trolled intercurrent illness or preexisting clinically significant
cardiac, hepatic, or renal disease were also excluded. Key
laboratory parameters for study enrollment included adequate
hematologic status (granulocytes1500/l, platelets100,000/
l), liver function (bilirubin within normal limits, aspartate
transaminase AST 2.0 upper limits of normal), and kidney
function (creatinine 2.0 mg/dl or creatinine clearance 60
ml/min).
Enrollment
Enrollment on this study was coordinated by the
CALGB Statistical Center and Data Operations through an
on-line patient registration system. Patients were enrolled and
treated on study at CALGB member institution. The study
was reviewed and approved by the institutional review boards
of all participating institutions, and signed informed consent
was obtained from all patients.
Treatment Plan
This study is a single-arm phase II study in which
patients were treated with carboplatin, etoposide, and exisu-
lind. Carboplatin (area under the curve 6) was administered
intravenously over 30 minutes on day 1. Etoposide 80 mg/m2
was administered intravenously over 30 to 60 minutes on day
1 (after carboplatin) and on days 2 and 3. Exisulind 250 mg
was administered orally twice a day beginning on day 1 and
continuing daily without interruption until completion of
chemotherapy. No maintenance therapy with exisulind was
administered. The carboplatin dose was calculated using the
Calvert formula.11 The creatinine clearance was estimated
using the Cockcroft-Gault formula.12 The maximum allow-
able creatinine clearance was 150 ml/min for males and 130
ml/min for females. Antiemetic regimens and other support-
ive measures were at the discretion of the individual treating
physician or institution.
Exisulind (APTOSYN, Sulindac Sulfone, IND #64733,
OSI Pharmaceuticals) was provided for this study by OSI
Pharmaceuticals. Commercially available carboplatin (Parapla-
tin, Bristol-Myers Squibb) and etoposide (VePesid, Bristol-
Myers Squibb) were given in accordance to the standard
preparation and administration guidelines in their respective
package inserts.
Clinical Evaluation
A comprehensive history and physical examination
(including performance status) were performed before enroll-
ment and before each treatment cycle. Complete blood counts
with differential and serum chemistries were also obtained.
Blood counts were repeated weekly and liver function tests
(serum glutamic-oxaloacetic transaminase (SGOT) alkaline
phosphatase, bilirubin) were repeated q2 weeks. Patients
were reassessed by RECIST criteria13 after every two cycles
and at the completion of therapy. The National Cancer Insti-
tute Common Toxicity Criteria version 2.0 was in effect
while this trial was conducted.
Dose Modification
Therapy was held for a granulocyte count of less than
1500/l or a platelet count of less than 100,000/l. Etoposide
and carboplatin doses were reduced by 25% for neutropenic
fever (absolute neutrophil count 500/l and temperature
100.5°C) requiring antibiotics or for grade 4 thrombocyto-
penia (platelets 10,000/l). Etoposide was reduced by 50%
for a serum creatinine of 2.0 to 2.9 mg/dl. Chemotherapy and
exisulind were held for a serum creatinine greater than 3.0
mg/dl. Exisulind was reduced by 25% for a SGOT (AST)
between 2.6 and 5.0 mg/dl. Both etoposide and exisulind
were reduced by 50% for a SGOT (AST) greater than 5.0
mg/dl. Etoposide and exisulind were held for bilirubin greater
than upper limits of normal. Once reduced, chemotherapy
doses were not reescalated.
Statistical Analysis
The primary objective was to evaluate the activity of
exisulind administered in combination with etoposide and
carboplatin for the treatment of patients with ES-SCLC. The
primary end point was the percentage of patients who live
longer than 12 months after the initiation of the experimental
treatment regimen. The target sample size of 41 eligible
patients was chosen such that the study has about 90% power
to differentiate a true 12-month survival rate of 40% or lower
versus 60% or higher at a one-sided significance level of 0.10.
Under this design, the decision rule will be as follows: if out
of the 41 patients, 21 or more remain alive 12 months after
the initiation of the treatment, it would be concluded that the
treatment regimen had sufficient merit to warrant further
investigation.
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Data collection was managed by the CALGB Statistical
Center. Data quality was ensured by careful review of
CALGB Statistical Center staff and by the study chair.
Statistical analyses were performed by CALGB statisticians.
Subjects were given a maximum of six cycles of treatment,
with toxicity evaluation every cycle and response evaluation
after every even-numbered cycle. Patients were followed for
response, failure-free survival, and overall survival. Patients
were considered evaluable for response if they received at
least two cycles of chemotherapy. The response rate and its
95% confidence interval (CI) were estimated. Failure-free
survival is defined as the time from the date of registration to
the date of disease progression or death, whichever comes
first. Overall survival is defined as the time from the date of
registration to the date of death of any causes. Kaplan-Meier
curves were used to characterize overall survival and failure-
free survival. Median survival and survival rate at 1 year and
their 95% CIs were computed.
As part of the quality assurance program of the
CALGB, members of the Data Audit Committee visit all
participating institutions at least once every 3 years to review
source documents. The auditors verify compliance with fed-
eral regulations and protocol requirements, including those
pertaining to eligibility, treatment, adverse events, tumor
response, and outcome in a sample of protocols at each
institution. Such on-site review of medical records was per-
formed for a subgroup of 18 patients (41%) of the 44 patients
under this study.
RESULTS
Patient Characteristics
The study was activated in June 2002 and closed in
August 2003. Forty-four patients were registered and all met
the eligibility creation of this study. All analyses were per-
formed on the 44 patients. There was no follow-up data on
one patient. The characteristics of the 44 eligible and treated
patients are shown in Table 1. The majority of the patients
were male (64%), Caucasian (95%), had a good performance
status (77%), and had experienced weight loss of less than
5% (59%). The median age of the patients was 61 (range
44–82) years. The median number of chemotherapy cycles
delivered was 6 (range 1–6), with 29 patients (66%) com-
pleting all six cycles of therapy.
Toxicity
All eligible patients were evaluated for adverse events.
Tables 2 and 3 summarize hematologic and nonhematologic
adverse events through all cycles of therapy. Overall, the
combination of carboplatin, etoposide, and exisulind was well
tolerated. Grade 3 or grade 4 hematological toxicity was seen
in 68% of the patients. No grade 5 hematological toxicity was
seen. The most frequent grade 3 hematological toxicities
were thrombocytopenia (36%), leukopenia (30%), neutrope-
nia (20%), and febrile neutropenia (16%). The most frequent
grade 4 hematological toxicities were neutropenia (43%) and
leukopenia (16%).
Twenty-five patients (57%) experienced grade 3 non-
hematological toxicity. Two patients experienced a grade 5
adverse event. One died of cerebrovascular ischemia. One
patient died of cardiac arrest. Both events were felt to be not
treatment related. One patient experienced grade 4 hypoka-
lemia. Patients who went off study before completing treat-
ment did so primarily because of progressive disease (16%).
TABLE 2. Hematologic Toxicity
Grade of Adverse Event
3 4
n % n %
Anemia 7 16 1 2
Febrile neutropenia 7 16
Leukopenia 13 30 7 16
Neutropenia 9 20 19 43
Thrombocytopenia 16 36
TABLE 3. Nonhematologic Toxicity (All Grade 3 with
Incidence Greater Than 5%)a
N %
Pain 6 14
Hyperglycemia 5 11
Fatigue 4 9
Dyspnea 3 7
Hyponatremia 3 7
Hypotension 3 7
Nausea 3 7
Anorexia 2 5
Dehydration 2 5
Diarrhea 2 5
Pancreatitis 2 5
Elevated alkaline phosphatase 2 5
Elevated creatinine 2 5
a One patient with grade IV hypokalemia (2%).
TABLE 1. Patient Characteristics
Characteristic
Overall, N  44
n %
Age
Median 61
Range 44–82
Sex
Female 16 36
Male 28 64
Race
Caucasian 42 95
African American 2 5
Performance status
0 12 27
1 22 50
2 6 14
Unknown 4 9
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Other reasons included adverse event (5%), death (7%), and
patient refusal (5%).
Response
The best response rate (complete and partial) is 77%
(95% CI: 62–89%). Complete responses were observed in
seven (16%) of the 44 patients. Two patients were not
evaluable for response because they did not receive two
cycles of chemotherapy. One patient died of cardiac arrest,
after receiving 1 day of chemotherapy. One patient was taken
off study because of newly diagnosed brain metastases after
receiving 1 day of chemotherapy. In addition, one patient had
no follow-up data and died of cerebrovascular ischemia after
receiving one cycle of chemotherapy. Table 4 summarizes the
frequency and percentage of best overall response for patients
with follow-up data.
Survival and Failure-Free Survival
All patients have been followed until death with sur-
vival time ranging from 1 to 44 months. One year overall
survival rate was 36.4% (95% CI: 24.6–53.8) and median
survival was 10.6 months (95% CI: 9.1–14.7) (Figure 1). One
year failure-free survival rate was 6.8% (95% CI: 2.3–20.3)
and median failure-free survival was 6.7 months (95% CI:
5.2–7.6) (Figure 2).
DISCUSSION
The combination of a platinum agent and etoposide
continues to be current standard of therapy13 for patients with
newly diagnosed ES-SCLC. Many different approaches have
been evaluated over the past three decades to improve the
outcomes of patients with ES-SCLC with virtually no suc-
cess. They include addition of a third agent,14,15 substitution
of etoposide with a different cytotoxic agent,16,17 dose dense
therapy,18 maintenance treatment,19–21 high-dose chemother-
apy,22 and the use of molecularly targeted agents.23
Although the combination of carboplatin, etoposide,
and exisulind was generally well tolerated with acceptable
hematologic and nonhematological toxicities, our study failed
to meet the prespecified goal in terms of overall survival.
Despite some promising early observations in the lab-
oratory, addition of exisulind to chemotherapy has so far
produced only disappointing results. Several phase II studies
using exisulind in combination with chemotherapy were re-
cently reported in non-small cell lung cancer (NSCLC)24–26
and prostate cancer.27 The ECOG performed a phase II
nonrandomized study of gemcitabine, carboplatin, and
exisulind24 in chemotherapy-naive patients with advanced
NSCLC. Even though, the study met its primary end point
of improving overall survival (18 month overall survival
30%), with the availability of other novel agents, this
regimen is not being pursued further. A phase I/II study of
gemcitabine and exisulind as second-line therapy in pa-
tients with advanced NSCLC through the University of
Wisconsin25 showed that the combination was well toler-
ated but did not show an advantage with regard to time to
progression or overall survival compared with historic
controls treated with chemotherapy alone. The combina-
tion of exisulind and weekly docetaxel in second-line
treatment of advanced NSCLC produced no objective
TABLE 4. Best Response (N  44 Patients)
Number of Patients
n %
Complete response 7 16
Partial response 27 61
Stable disease 5 11
Progressive disease 2 5
Unevaluable 2 5
No data 1 2
Best response rate (95% CI) 77% (62–89%)
CI, confidence interval.
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FIGURE 1. Kaplan-Meier curve of
the overall survival for 44 patients
who received the combination
treatment.
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responses.26 A phase II study of this same combination in
androgen independent prostate cancer27 was terminated
early because of toxicities. Because of the lack of activity
seen so far, there are only two studies with exisulind
currently recruiting patients—one looking at apoptosis
before radical prostatectomy for prostate cancer28 and one
looking at progression and survival after radical prostatec-
tomy compared with placebo.29 There are no further stud-
ies with exisulind in the active treatment of cancer in
combination with systemic chemotherapy.
Other novel therapies are currently being investigated
for the treatment of small cell lung cancer23 but have shown
little promise. Molecular targeted therapies such as imatinib30
and gefitinib31 failed to show improvement in response or
survival. The CALGB and North Central Cancer Treatment
Group conducted a phase II trial of imatinib in patients with
c-kit expressing relapsed small-cell lung cancer.30 Gefitinib
was studied in 19 patients with chemosensitive and chemore-
fractory relapsed small cell cancer performed by the Hoosier
Oncology Group31 and also failed to show any activity with
only two patients achieving stable disease as their best re-
sponse. Matrix metalloproteinase inhibitors, such as mari-
mastat, showed no survival benefit in a phase III study as
maintenance therapy in patients with SCLC who responded to
first-line therapy.32 A randomized phase III study of etopo-
side and carboplatin plus thalidomide or placebo during
chemotherapy and as maintenance therapy in chemo-naive
patients with SCLC was presented at the 12th World Con-
ference on Lung Cancer.33 Neither survival nor progression-
free survival was improved, and the addition of thalidomide
was associated with an increase in thrombotic events.
A phase II study of cisplatin, etoposide, and bevaci-
zumab in previously untreated ES-SCLC by ECOG showed
an overall response rate of 69% with four patients achieving
complete response.34 The CALGB reported a phase II study
of bevacizumab in combination with cisplatin and irinotecan
in chemo-naive patients with ES-SCLC which showed an
overall response rate of 75% with three patients achieving
complete responses.35 Although the ECOG study met its
predetermined end point, the CALGB study did not. It is
hoped that an ongoing randomized phase II study would shed
more light on the role of bevacizumab in combination with
chemotherapy in SCLC.
Although prophylactic cranial irradiation has been rou-
tinely offered for patients with limited stage small cell lung
cancer who have achieved complete response or near com-
plete response after concurrent chemoradiation,36 it has been
shown that prophylactic cranial irradiation improves survival
in patients with extensive stage SCLC as well.37
A novel potential strategy worth pursuing is targeting
the hedgehog signaling pathway.38 Preliminary data suggest
that this pathway is active in small cell lung cancer.39 Mod-
ulating this pathway hopefully would lead to the long awaited
breakthrough in the treatment of small cell lung cancer.
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